V
Vifor Pharma AG
SIX:VIFN
Vifor Pharma AG
SIX:VIFN
Price:
166.15 CHF
0.48%
Market Closed
Updated:
May 17, 2024
Vifor Pharma AG
Cost of Revenue
|
Vifor Pharma AG
Cost of Revenue Peer Comparison
Comparables:
NOVN
NLSP
ROG
S
SDZ
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
V
|
Vifor Pharma AG
SIX:VIFN
|
Cost of Revenue
-CHf671.8m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
13%
|
|
|
Novartis AG
SIX:NOVN
|
Cost of Revenue
-$15.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
1%
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Cost of Revenue
-CHf15.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-2%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Cost of Revenue
-$4.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Vifor Pharma AG's Cost of Revenue?
Cost of Revenue
-671.8m
CHF
-671.8m
CHF
Based on the financial report for Dec 31, 2021, Vifor Pharma AG's Cost of Revenue amounts to -671.8m CHF.
What is Vifor Pharma AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
13%
13%
Over the last year, the Cost of Revenue growth was 4%. The average annual Cost of Revenue growth rates for Vifor Pharma AG have been -1% over the past three years , -9% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet
